Allison Schwartz, a director of Bio-Rad Laboratories, Inc., filed a Form 4 on September 3, 2026, disclosing transactions in Bio-Rad Class A common stock on September 1, 2026, stemming from the vesting of restricted stock units.
Key Highlights
- RSU vesting: 117 shares of Bio-Rad Class A common stock were acquired on September 1, 2026, from the vesting of restricted stock units, at a price of $0.
- Tax withholding disposition: 43 shares were disposed of on September 1, 2026, at a price of $380.96 per share, coded as an F (tax withholding) transaction.
- Resulting direct ownership: Following both transactions, Schwartz directly holds 1,530 shares of Bio-Rad Class A common stock.
- Remaining RSUs: 75 restricted stock units remain outstanding after the reported transactions, held directly.
- Grant history: The 42 RSUs that fully vested originated from a September 1, 2022 grant of 167 units, vesting in four equal annual installments; the 75 RSUs that partially vested originated from a September 1, 2023 grant of 298 units on the same schedule.
RSU Vesting and Share Withholding Details for Bio-Rad Director Schwartz
According to the filing, Allison Schwartz, identified as a director of Bio-Rad Laboratories, Inc. (NYSE:BIO and BIO.B), reported two transactions on September 1, 2026. The first was an "M" coded transaction in which 117 shares of Bio-Rad Class A common stock were acquired at $0 as a result of restricted stock unit vesting. These shares came from two separate RSU grants: 42 units from a September 1, 2022 grant and 75 units from a September 1, 2023 grant, each vesting in four equal annual installments beginning on the first anniversary of the grant date.
The filing further discloses an "F" coded transaction in which 43 shares were disposed of at $380.96 per share on the same date. The F code indicates shares withheld for payment of taxes upon vesting. After these two transactions, Schwartz's direct beneficial ownership in Bio-Rad Class A common stock stands at 1,530 shares, according to the filing.
In the derivative securities table, the filing shows that the 42 RSUs from the 2022 grant are now fully settled, leaving a balance of zero. The 75 RSUs from the 2023 grant remain outstanding with a balance of 75, held directly. Each restricted stock unit represents, as the filing states, "a contingent right to receive one share of Bio-Rad Class A common stock."
What Was Disclosed
The Form 4 filed by director Allison Schwartz covers RSU vesting and a related tax-withholding share disposition on September 1, 2026, resulting in direct ownership of 1,530 shares of Bio-Rad Class A common stock and 75 remaining RSUs.




Please wait processing your request...